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See related research by Krinsley and Preiser, http://www.ccforum.com/content/19/1/179With great interest, we followed the recent publication
[1] regarding glucose management. The observational
study evaluates patients in a medical-surgical intensive
care unit (ICU) and reports on associations between
time in targeted blood glucose range (TIR) and ICU
mortality. The authors defined a TIR of 70–140 mg/dl
(local hospital policy). The observed association with
mortality was limited to non-diabetic patients and this is
highly relevant. The presence of diabetes seems to re-
duce a protective effect of intensive blood glucose man-
agement in non-diabetics. A protective effect related to
an intrinsic non-glucose-regulating mechanism of insu-
lin [2, 3] was discussed but could also be altered by insu-
lin resistance. Here, HBA1c measured on ICU admission
or other surrogates (e.g., C-peptide related to blood glu-
cose) could serve as potent biomarkers to identify pa-
tients who may benefit from glucose management. Every
observation is exploratory and it is impossible to draw
conclusions on causality. Other interacting factors like
quality of infection management are also strongly related
to ICU survival [4], and patients with diabetes have an
increased risk to develop severe infections [2]. Interest-
ingly, the findings of Krinsley and Preiser [1] are in line
with results from another study in surgical ICU patients
[5]. When slightly different cutoffs for low TIR were
used, this measurement was associated with ICU mortal-
ity (odds ratio = 3.69, P = 0.013) for patients with lower
achieved quality in blood glucose management [5].
In contrast to most published guidelines, future rec-
ommendations may need to include individualized algo-
rithms (e.g., for patients with and patients without
diabetes mellitus) [2]. In this context, we agree with the
authors that a single target range of blood glucose man-
agement in the ICU setting seems to be arbitrary and* Correspondence: sascha.tafelski@charite.de
Department of Anaesthesiology and Intensive Care,
Charité-Universitaetsmedizin Berlin, Campus Charité Mitte and Campus
Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
© 2015 Tafelski et al. Open Access This article
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zefurther studies are required to study individualized ther-
apy algorithms in both the surgical and the non-surgical
ICU setting.
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